Michael J. Birrer
0000-0002-3861-4521
Publication & Citation Trends
Publications
0 total
Exploring survival-associated transcriptomic subtypes in ovarian cancer using RNAseq from FFPE tissues in a clinical trial cohort
Cited by 0
Semantic Scholar
Abstract 3970: Genome wide testing of archived ovarian and uterine carcinosarcoma FFPE tissue using FusionPlus Hi-C to determine HRD status
Cited by 0
Semantic Scholar
Abstract B017: Phase 2 Study of NP-G2-044, a Novel Fascin Inhibitor, in Combination with Anti-PD-1 Therapy in Patients with Solid Tumors Resistant to Prior Anti-PD-1 Therapy
Cited by 0
Semantic Scholar
Single-cell analysis of ovarian myeloid cells identifies age associated changes in macrophages and signaling dynamics.
Cited by 3
Semantic Scholar
Abstract A044: Application of HRDefine: a biomarker for identifying root causes of homologous recombination deficiency to a phase 3, randomized, placebo-controlled trial of veliparib in front-line treatment of advanced ovarian cancer (VELIA/GOG-3005)
Cited by 0
Semantic Scholar
A spatial proteomic study of platinum refractory HGSOC implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment.
Cited by 3
Semantic Scholar
Research Topics
Ovarian cancer diagnosis and treatment
(444)
Cancer-related molecular mechanisms research
(85)
Cancer Genomics and Diagnostics
(80)
Endometrial and Cervical Cancer Treatments
(77)
RNA modifications and cancer
(76)
Affiliations
The Wistar Institute
University of Arkansas at Little Rock
Boston University
University of North Carolina at Chapel Hill
James S. McDonnell Foundation